Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
- Revenue in USD (TTM)7.17bn
- Net income in USD64.47m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunitybio Inc | 302.00k | -600.96m | 5.29bn | 628.00 | -- | -- | -- | 17,518.20 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.45bn | 927.00 | -- | 18.35 | -- | 7.01 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Organon & Co | 6.35bn | 1.05bn | 5.61bn | 10.00k | 5.35 | 116.20 | 4.34 | 0.8833 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
BridgeBio Pharma Inc | 218.60m | -538.26m | 5.63bn | 550.00 | -- | -- | -- | 25.76 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.69bn | 373.00 | 18.49 | 31.98 | 14.19 | 6.59 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Exelixis Inc | 1.85bn | 205.05m | 6.09bn | 1.31k | 32.34 | 2.90 | 26.45 | 3.30 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Cytokinetics, Inc. | 3.75m | -530.60m | 6.24bn | 423.00 | -- | -- | -- | 1,663.63 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Revolution Medicines Inc | 4.57m | -484.27m | 6.50bn | 411.00 | -- | 3.77 | -- | 1,424.03 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Grifols SA - ADR | 7.17bn | 64.47m | 6.51bn | 23.74k | 78.59 | 0.8255 | 9.62 | 0.9087 | 0.098 | 0.098 | 10.65 | 9.33 | 0.3068 | 1.23 | 9.86 | 301,781.60 | 0.8408 | -- | 1.06 | -- | 37.84 | -- | 2.74 | -- | 1.29 | 1.56 | 0.5593 | -- | 8.71 | -- | -71.52 | -- | -- | -- |
Blueprint Medicines Corp | 282.21m | -288.29m | 6.57bn | 645.00 | -- | 21.15 | -- | 23.29 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Intra-Cellular Therapies Inc | 513.93m | -110.87m | 6.86bn | 610.00 | -- | 10.57 | -- | 13.35 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.87bn | 2.80k | 22.49 | 1.86 | 7.02 | 1.79 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Viking Therapeutics Inc | 0.00 | -93.72m | 7.39bn | 28.00 | -- | 7.91 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Bellring Brands Inc | 1.84bn | 191.50m | 7.49bn | 420.00 | 39.92 | -- | 31.66 | 4.06 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.67bn | 355.00 | -- | 13.57 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 20.75m | 7.94% |
Brandes Investment Partners LPas of 31 Mar 2024 | 17.11m | 6.55% |
Millennium Management LLCas of 31 Mar 2024 | 14.35m | 5.49% |
Permian Investment Partners LPas of 31 Mar 2024 | 12.84m | 4.91% |
Black Creek Investment Management, Inc.as of 31 Mar 2024 | 11.46m | 4.38% |
Flat Footed LLCas of 31 Mar 2024 | 7.04m | 2.69% |
Armistice Capital LLCas of 31 Mar 2024 | 6.65m | 2.54% |
Pictet Asset Management SAas of 31 Mar 2024 | 6.39m | 2.45% |
Harris Associates LPas of 31 Mar 2024 | 3.86m | 1.48% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 3.31m | 1.27% |